Development of quality-by-design analytical methods.

Quality-by-design (QbD) is a systematic approach to drug development, which begins with predefined objectives, and uses science and risk management approaches to gain product and process understanding and ultimately process control. The concept of QbD can be extended to analytical methods. QbD mandates the definition of a goal for the method, and emphasizes thorough evaluation and scouting of alternative methods in a systematic way to obtain optimal method performance. Candidate methods are then carefully assessed in a structured manner for risks, and are challenged to determine if robustness and ruggedness criteria are satisfied. As a result of these studies, the method performance can be understood and improved if necessary, and a control strategy can be defined to manage risk and ensure the method performs as desired when validated and deployed. In this review, the current state of analytical QbD in the industry is detailed with examples of the application of analytical QbD principles to a range of analytical methods, including high-performance liquid chromatography, Karl Fischer titration for moisture content, vibrational spectroscopy for chemical identification, quantitative color measurement, and trace analysis for genotoxic impurities.

[1]  Marion J. Chatfield,et al.  Design and analysis of method equivalence studies. , 2009, Analytical chemistry.

[2]  Bernard A Olsen,et al.  A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603). , 2008, Journal of pharmaceutical and biomedical analysis.

[3]  Lawrence X. Yu Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[4]  David Q. Liu,et al.  Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping. , 2010, Journal of pharmaceutical and biomedical analysis.

[5]  Frank David,et al.  Analysis of potential genotoxic impurities in pharmaceuticals by two-dimensional gas chromatography with Deans switching and independent column temperature control using a low-thermal-mass oven module , 2010, Analytical and bioanalytical chemistry.

[6]  K. Ishikawa What Is Total Quality Control , 1985 .

[7]  I. Krull,et al.  A Quality-by-Design Methodology for Rapid LC Method Development, Part III , 2008 .

[8]  Ronald G Iacocca,et al.  Particle engineering: a strategy for establishing drug substance physical property specifications during small molecule development. , 2010, Journal of pharmaceutical sciences.

[9]  Ira S. Krull,et al.  Analytical Method Transfer , 2012 .

[10]  Antonio Scipioni,et al.  FMEA methodology design, implementation and integration with HACCP system in a food company , 2002 .

[11]  Marianthi Ierapetritou,et al.  Quality by Design Methodology for Development and Scale-up of Batch Mixing Processes , 2008, Journal of Pharmaceutical Innovation.

[12]  Steven Kozlowski,et al.  Considerations for Biotechnology Product Quality by Design , 2008 .

[13]  H. Wu,et al.  Quality-by-design (QbD): an integrated approach for evaluation of powder blending process kinetics and determination of powder blending end-point. , 2009, Journal of pharmaceutical sciences.

[14]  Gail Sofer,et al.  Viral Clearance: A Strategy for Quality by Design and the Design Space , 2008 .

[15]  Yan Li,et al.  A PHASE APPROPRIATE APPROACH TO RP-HPLC METHOD DEVELOPMENT FOR IMPURITIES ANALYSIS IN ACTIVE PHARMACEUTICAL INGREDIENTS VIA CONTINUOUS MANUFACTURING PROCESS UNDERSTANDING , 2010 .

[16]  Jiju Antony,et al.  Design of experiments for engineers and scientists , 2003 .

[17]  Mansoor A. Khan,et al.  Quality-by-Design (QbD): an integrated process analytical technology (PAT) approach for real-time monitoring and mapping the state of a pharmaceutical coprecipitation process. , 2010, Journal of pharmaceutical sciences.

[18]  Frederick G. Vogt,et al.  A Systematic Method Development Strategy for Quantitative Color Measurement in Drug Substances, Starting Materials, and Synthetic Intermediates , 2011, Journal of Pharmaceutical Innovation.

[19]  David Q. Liu,et al.  Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.

[20]  Radhakrishna Tirumalai,et al.  Terminal Sterilization and Potential for Parametric Release , 2005 .

[21]  D. T. Witte,et al.  Examples of NIR based real time release in tablet manufacturing. , 2007, Journal of pharmaceutical and biomedical analysis.

[22]  Hiromitsu Kumamoto,et al.  Probabilistic Risk Assessment and Management for Engineers and Scientists , 1996 .

[23]  Joel Young,et al.  Analytical methodology transfer , 2011 .

[24]  Kingman Ng,et al.  Application of Quality by Design and Risk Assessment Principles for the Development of Formulation Design Space , 2008 .

[25]  Anurag S. Rathore,et al.  QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS , 2008 .

[26]  David Q. Liu,et al.  Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process. , 2009, Journal of pharmaceutical and biomedical analysis.

[27]  Jianmei Kochling,et al.  Introducing a Science-Based Quality by Design Concept to Analytical Methods Development , 2010 .

[28]  David Q. Liu,et al.  A Systematic Method Development Strategy for Determination of Pharmaceutical Genotoxic Impurities , 2010 .

[29]  P. Borman,et al.  Acceptance criteria for method equivalency assessments. , 2009, Analytical chemistry.

[30]  Simon J. Bale,et al.  Quality by Design for Analytical Methods , 2010 .

[31]  K. Ishikawa What is total quality control the japanese way , 2002 .